You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Details for Patent: RE44638

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE44638 protect, and when does it expire?

Patent RE44638 protects ZYDELIG and is included in one NDA.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: RE44638

Title:	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Abstract:	The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K.delta. activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
Inventor(s):	Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA)
Assignee:	ICOS Corporation (Indianapolis, IN)
Application Number:	13/730,256
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent RE44638

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE44638

PCT Information
PCT Filed	May 12, 2005	PCT Application Number:	PCT/US2005/016778
PCT Publication Date:	December 01, 2005	PCT Publication Number:	WO2005/113556

International Family Members for US Patent RE44638

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005245875	⤷ Try a Trial
Australia	2009230739	⤷ Try a Trial
Canada	2566609	⤷ Try a Trial
China	101031569	⤷ Try a Trial
China	102229609	⤷ Try a Trial
Cyprus	1118493	⤷ Try a Trial
Cyprus	1118516	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.